Skip to main content
Premium Trial:

Request an Annual Quote

Integrated DNA Technologies to Manufacture Quanta miRNA Assays

Premium

Quanta Biosciences said this week that Integrated DNA Technologies will manufacture assays that Quanta has developed for quantifying microRNAs.

Under the terms of the deal, IDT will produce the assays, which will allow scientists to detect and profile mature miRNA sequences; and will market them through an online catalog directly to customers of Quanta.

Quanta said that early-access customers, who have not been disclosed, have used the assays for toxicology screening during drug development; and quality control of stem cell pluripotency and differentiation.

Financial terms of the deal were not disclosed.

Based in Gaithersburg, Md., Quanta develops reagents for PCR, qPCR, and cDNA applications.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.